Paul L. Berns, See Remarks at Neumora Therapeutics, Inc. (NMRA), sold 13,871 shares at $1.69 ($23K) on 2025-02-18, disclosed to the SEC on 2025-02-20.
Scheduled sale ($23k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| NMRA | SELL | 2026-02-19 | $34K | — | Filing → |
| MTSR | BUY | 2025-02-03 | $14.2M | — | Filing → |
| JAZZ | SELL | 2021-08-09 | $223K | — | Filing → |